NeuClone is a perfect example of how Australian innovation is generating global interest and creating Australian jobs.
NeuClone’s patented technology enhances the production of biologic drugs by causing cells to increase protein expression, creating cost-efficiencies for
manufacturers. This has led to a partnership with the Serum Institute of India, the world’s largest vaccine maker.
NeuClone’s disruptive technologies will deliver a significant social impact and Dr Sunstrom, as the inventor, founder and CEO of NeuClone, is a very worthy
recipient of this scholarship.
Dr Sunstrom will attend Harvard Business School’s Disruptive Innovation—Strategies for a Successful Enterprise program, delivered at Boston, Massachusetts
in July 2017.
The scholarship reflects the Turnbull Government’s commitment to supporting female entrepreneurship and helping businesses take advantage of growing global
demand for Australia’s high quality goods, services and intellectual property.